Pharmaceutical Pipeline Market Assessment 2016 Covering Analysis of 20,756 products

RnRMarketResearch.com adds “Innovation Tracking Factbook 2016 – An Assessment of the Pharmaceutical Pipeline Market” to its database providing analysis of the 20,756 products currently in the pharmaceutical industry pipeline, from the Discovery stage through to Pre-registration and split into therapy areas and key indications. It also includes a detailed contextual analysis of the key drivers of this pipeline, along with an assessment of companies present in the pipeline and historical deal value and volume. The report state that the growth in drug research and development (R&D) costs appears to stem from an increased clinical failure rate and emphasis on proving superiority over comparator drugs in technology assessments, as well as an increasing level of sophistication from payers when assessing the cost-effectiveness of drugs.

Pharmaceutical Companies Increasingly Looking to Innovate High-Risk, First-in-Class Products with the cost of bringing a single novel drug to market estimated to be $2.6 billion in 2015, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximize revenue and stay ahead of competition.

Get discount on this research report at http://www.rnrmarketresearch.com/contacts/discount?rname=635387 .

This pipeline is also benchmarked against its size across each segment in 2015, and an assessment of the level of first-in-class innovation is provided. In addition, a detailed contextual analysis of the key drivers of this pipeline is provided, in addition to an assessment of companies present in the pipeline and historical deal value and volume.

Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. The market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue.

A particular focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent decades, in addition to an increase in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also increased. The proportion of first-in-class approvals has increased steadily each year since 1994, with the exception of the years 2005-2008, when the proportion was relatively high.

Complete research report of 70 pages with TOC is available at http://www.rnrmarketresearch.com/innovation-tracking-factbook-2016-an-assessment-of-the-pharmaceutical-pipeline-market-report.html .

Scope

• What is the current size and composition of the pharmaceutical industry pipeline and how has it changed since Q1 2015? What can we learn from this?
• The largest therapy area, by a substantial margin, is oncology, and, with growth in the pipeline sizes for all major oncology indications since Q1 2015, this trend appears set to continue. Why is this the case?
• What is the overall advantage for companies including first-in-class product developments in their pipeline portfolio, rather than opting for better-characterized established molecular targets?
• What factors have been driving the increasing number of first-in-class product approvals over recent decades?
• What strategies have companies typically been pursuing with their pipeline portfolio, in terms of how diverse, specialized or innovative they have been? Specifically, what strategies have the top 25 pharmaceutical companies been following?
• What key discernible trends have appeared in the strategic consolidations landscape in the past decade and which disease areas have been most active?

List of Tables

Table 1: Trends in Clinical Trial Protocol Complexity, 2000-2011
Table 2: Pipeline Products by Therapy Area, 2015-Q1 2016
Table 3: Number of Clinical Trials Initiated by Therapy Area, 2006-2015
Table 4: Pipeline Products by Therapy Area and Stage of Development
Table 5: Pipeline Products by Therapy Area and Molecule Type, Q1 2016
Table 6: First-in-Class Pipeline Products by Therapy Area, Q1 2015-Q1 2016
Table 7: First-in-Class Oncology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 8: First-in-Class Infectious Diseases Pipeline Products by Indication, Q1 2015-Q1 2016
Table 9: First-in-Class Central Nervous System Disorder Pipeline Products by Indication, Q1 2015-Q1 2016
Table 10: First-in-Class Immunology Pipeline Products by Indication, Q1 2015-Q1 2016
Table 11: Licensing Deal Value and Volume, 2006-Q1 2016
Table 12: Number of Licensing Deals by Therapy Area, 2006-Q1 2016
Table 13: Aggregate Licensing Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 14: Co-development Deal Value and Volume, 2006-Q1 2016
Table 15: Co-development Deal Volume by Therapy Area, 2006-Q1 2016
Table 16: Co-development Deal Value by Therapy Area ($m), 2006-Q1 2016
Table 17: Merger and Acquisition Deal Value and Volume, 2006-Q1 2016
Table 18: Capital Raising Value and Volume, 2006-Q1 2016